Manufacturing contract for world-first cancer vaccine

Anticipating a US Food and Drug Administration (FDA) approval this year, Dendreon has awarded Diosynth Biotechnology with a long-term contract to supply its novel vaccine for prostate cancer – the third most common cancer in the world. If approved, Dendreon's Provenge (sipuleucel-T) will be the first cancer vaccine ever to reach the market. Provenge may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. It is delivered via Dendreon's proprietary antigen delivery cassette technology, which uses a recombinant form of an antigen found in approximately 95 per cent of prostate cancers, prostatic acid phosphatase (PAP), to stimulate the patient's immune system to attack the cancer cells. "Source":[ http://www.in-pharmatechnologist.com/news/ng.asp?n=66390-diosynth-biotechnology-dendreon-provenge-prostate-cancer-antigen ].

---